Genomic Health (NASDAQ:GHDX) reported Q2 2018 earnings this Afternoon, coming in at $0.23 per share, beating Wall Street’s estimates of $0.07 per Share. Revenue for the quarter came in at $95.60 million beating analyst estimates of $92.23 million Recent Insider Trading for Genomic Health (NASDAQ:GHDX)
- On 7/16/2018 Kimberly J. Popovits, Insider, sold 10,000 with an average share price of $53.27 per share and the total transaction amounting to $532,700.00.
- On 7/9/2018 Steven Shak, Insider, sold 5,500 with an average share price of $49.56 per share and the total transaction amounting to $272,580.00.
- On 6/14/2018 Kimberly J. Popovits, Insider, sold 10,000 with an average share price of $48.89 per share and the total transaction amounting to $488,900.00.
- On 6/11/2018 Steven Shak, Insider, sold 5,500 with an average share price of $50.22 per share and the total transaction amounting to $276,210.00.
- On 6/4/2018 James J. Vaughn, Insider, sold 93,414 with an average share price of $45.78 per share and the total transaction amounting to $4,276,492.92.
- On 5/14/2018 Kimberly J. Popovits, CEO, sold 10,000 with an average share price of $38.09 per share and the total transaction amounting to $380,900.00.
About Company Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype DX AR-V7 Nucleus Detect test for men with metastatic castration-resistant prostate cancer. The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreement with Epic Sciences, Inc.; license and development agreement with Biocartis N.V.; license agreement with Cleveland Diagnostics, Inc.; and a research collaboration agreement with Janssen Pharmaceuticals. The company was founded in 2000 and is based in Redwood City, California.Recent Analyst Rating for Genomic Health (NASDAQ:GHDX)
Recent Trading for Genomic Health (NASDAQ:GHDX) Shares of Genomic Health closed the previous trading session at with shares trading hands.